Latest Europe News

Australian Agricultural Company Limited (AACo) reported a record first-half operating profit of $39.8 million, boosted by higher beef and cattle prices and volumes, alongside strategic investments in feedlot expansion and carbon projects.

Australian Agricultural Company Limited (AACo) has reported a record first-half operating profit of $39.8 million, nearly doubling from the previous year, driven by higher beef prices and strategic live cattle sales. The company’s investments in genetics, carbon projects, and global market expansion set a strong foundation for future growth.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

Altamin Limited has appointed GBA Capital as lead manager to place shortfall shares from its recent entitlement offer, offering broker options as part of the arrangement. This move aims to bolster support for its critical minerals projects in Italy while engaging new and existing investors.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Nufarm Limited has announced Rico Christensen as its new CEO, succeeding Greg Hunt in January 2026, marking a strategic leadership transition with a focus on operational excellence and growth.

Nufarm Limited reported a 3% revenue increase to $3.4 billion in FY2025, driven by strong crop protection growth, while restructuring in Seed Technologies led to a statutory loss of $165 million. The company forecasts earnings growth and leverage reduction in FY2026.

Nufarm’s FY25 results reveal robust growth in crop protection and a strategic reset in seed technologies, with a significant reduction in net debt setting the stage for a stronger FY26.

Nufarm Limited posted a $165.3 million statutory loss for FY25, driven by significant restructuring charges and omega-3 price declines, while announcing a CEO transition effective January 2026.

EML Payments has affirmed its FY26 underlying EBITDA guidance of A$58-63 million following a solid Q1 trading update, underpinned by a growing new program pipeline and operational efficiencies.

Prescient Therapeutics has achieved a key regulatory milestone with the European Medicines Agency granting Orphan Drug Designation for its PTX-100 therapy targeting Cutaneous T-cell Lymphomas, enhancing its commercial and clinical prospects in Europe.

Vulcan Energy reports robust drilling results and lithium grade confirmation from its Phase One Lionheart Project wells in Germany, reinforcing confidence in its sustainable lithium production plans.